Thu, May 15, 1:37 PM (39 days ago)
**International Isotopes Inc. (INIS) - Q1 2025 Financial Summary** **Financial Health and Performance Metrics:** - **Revenue:** $3,238,900 (up 12% from Q1 2024). - **Gross Profit:** $2,032,037 (up 9% from Q1 2024). - **Net Loss:** $112,694 (improved from $154,051 in Q1 2024). - **Operating Expenses:** $2,097,053 (down 2% from Q1 2024). - **Cash Flow:** Net cash used in operating activities was $5,119 (down from $412,444 provided in Q1 2024). **Segment Performance:** - **Theranostics Products:** Sales down 6% due to a temporary supplier outage. - **Cobalt Products:** Sales down 69% due to timing of high-value sales. - **Nuclear Medicine Standards:** Sales up 73% due to resolved global shortages. - **Medical Device Products:** New segment with $52,630 in sales. - **Fluorine Products:** No revenue, but expenses down slightly. **Key Financial Metrics:** - **Current Assets:** $4,561,822 (down from $4,985,826 in Q4 2024). - **Long-term Assets:** $13,003,815 (up from $12,175,142 in Q4 2024). - **Total Liabilities:** $13,225,970 (up from $12,813,960 in Q4 2024). - **Stockholders' Equity:** $4,339,667 (down from $4,347,008 in Q4 2024). **Trends and Uncertainties:** - **Positive Trends:** Increased sales in Nuclear Medicine Standards, improved gross profit margins. - **Negative Trends:** Decreased sales in Theranostics and Cobalt Products, increased operating expenses in Medical Device Products. - **Uncertainties:** Dependence on a few key suppliers, potential delays in regulatory approvals, and the impact of the planned sale of the Fluorine Products segment. **Future Operations Impact:** - **Strategic Initiatives:** Continued focus on Theranostics Products, expansion of Medical Device Products, and potential sale of Fluorine Products segment. - **Financial Outlook:** Expects cash from operations and equity financing to fund operations for the next twelve months, but future liquidity depends on various factors. **Ticker:** INIS